Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30618514 | 1.00 | CYP1A2 (0.47) | CYP1A2MTNR1AMTNR1BIDO1PPARD | |
| SCHEMBL5468751 | 0.92 | ALDH1A1 (0.49) | CYP1A2ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL9181002 | 0.90 | ALDH1A1 (0.46) | CYP1A2IDO1ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL30618512 | 0.86 | PPARD (0.45) | PPARDHSD17B1ALDH1A1FFAR1 | |
| SCHEMBL1470470 | 0.85 | MTNR1A (0.50) | MTNR1AMTNR1BPPARDALDH1A1HTR6 | |
| SCHEMBL19984866 | 0.85 | CYP1A2 (0.49) | CYP1A2MTNR1AMTNR1BIDO1NOTUM | |
| SCHEMBL16077453 | 0.83 | PPARD (0.53) | PPARDHSD17B1FFAR1CYP11B1CYP11B2 | |
| SCHEMBL13284781 | 0.83 | PPARD (0.53) | PPARDHSD17B1FFAR1CYP11B1CYP11B2 | |
| SCHEMBL29960447 | 0.82 | CYP1A2 (0.42) | CYP1A2IDO1HSD17B1NOTUMCYP11B1 | |
| SCHEMBL10744543 | 0.82 | CYP1A2 (0.52) | CYP1A2IDO1ALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | claimed |
| EP-4510829-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | The Regents of University of California (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | claimed |
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | disclosed |
| EP-4510829-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | The Regents of University of California (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3512843-B1 | PLANT GROWTH REGULATOR COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-11136292-B2 | Plant growth regulator compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-05 | — | — | US | disclosed |
| US-6133446-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| CN-1046507-C | Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases | UPJOHN CO (US) | 1999-11-17 | — | — | CN | disclosed |
| EP-0661273-B1 | Indane derivatives and processes for preparing the same | TANABE SEIYAKU CO (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-5877317-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5686452-A | PROTECTING FROM ENDOTOXIN SHOCK; TREATMENT OF NEPHRITIS | TANABE SEIYAKU CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| CN-1139431-A | Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases | PHARMACIA & UPJOHN CO LLC (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0661273-A1 | Indane derivative and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250287942-A1 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | ACHE, BCHE, DDT | CYP1A2 1974/4885MTNR1A 1850/4885MTNR1B 1961/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | CYP1A2 201/4885MTNR1A 395/4885MTNR1B 220/4885 |
| US-11136292-B2 | Plant growth regulator compounds | FGF1, MST1, CDC20 | CYP1A2 3770/4885MTNR1A 1155/4885MTNR1B 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.